Novo Nordisk A/S (NYSE:NVO) Shares Acquired by Dimension Capital Management LLC

Dimension Capital Management LLC boosted its stake in Novo Nordisk A/S (NYSE:NVO) by 30.5% in the fourth quarter, Holdings Channel.com reports. The firm owned 3,213 shares of the company’s stock after acquiring an additional 750 shares during the quarter. Dimension Capital Management LLC’s holdings in Novo Nordisk A/S were worth $276,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Diversified Trust Co lifted its holdings in Novo Nordisk A/S by 13.9% in the 4th quarter. Diversified Trust Co now owns 3,246 shares of the company’s stock worth $279,000 after buying an additional 395 shares in the last quarter. First Hawaiian Bank increased its position in Novo Nordisk A/S by 30.3% in the 4th quarter. First Hawaiian Bank now owns 22,259 shares of the company’s stock valued at $1,915,000 after acquiring an additional 5,171 shares during the period. ORG Partners LLC lifted its holdings in Novo Nordisk A/S by 181.7% in the fourth quarter. ORG Partners LLC now owns 1,003 shares of the company’s stock worth $86,000 after purchasing an additional 647 shares during the period. Wealth Enhancement Advisory Services LLC lifted its position in Novo Nordisk A/S by 0.4% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 290,489 shares of the company’s stock worth $24,988,000 after purchasing an additional 1,051 shares during the period. Finally, A. D. Beadell Investment Counsel Inc. grew its holdings in Novo Nordisk A/S by 41.1% during the fourth quarter. A. D. Beadell Investment Counsel Inc. now owns 13,012 shares of the company’s stock worth $1,119,000 after acquiring an additional 3,787 shares during the period. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Price Performance

Shares of NYSE:NVO opened at $67.49 on Thursday. Novo Nordisk A/S has a twelve month low of $57.00 and a twelve month high of $148.15. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $302.88 billion, a PE ratio of 20.51, a P/E/G ratio of 0.90 and a beta of 0.65. The company has a 50-day moving average price of $70.14 and a two-hundred day moving average price of $86.94.

Analyst Ratings Changes

A number of analysts have recently issued reports on the company. BMO Capital Markets restated a “market perform” rating and issued a $64.00 target price (down previously from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. Dbs Bank lowered shares of Novo Nordisk A/S to a “sell” rating in a report on Friday, April 25th. Kepler Capital Markets upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Thursday, March 13th. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. Finally, BNP Paribas started coverage on shares of Novo Nordisk A/S in a research note on Tuesday, April 15th. They issued an “underperform” rating for the company. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Novo Nordisk A/S presently has an average rating of “Moderate Buy” and an average price target of $135.00.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.